Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rank in Stocks
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Share Price
$4.48
Market Cap
$4.99B
Change (1 day)
-5.20%
Change (1 year)
-41.89%
Country
CN
Trade Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Category
Healthcare
Revenue for Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Revenue in Jun 2026 TTM: $703.92M
According to Shenzhen Salubris Pharmaceuticals Co., Ltd. latest financial reports the company's current revenue (TTM) is $703.92M. In 2024 the company made a revenue of $549.69M an increase over the revenue in the year 2023 that was $475.42M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Shenzhen Salubris Pharmaceuticals Co., Ltd. from 2006 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $703.92M | 14.35% |
| 2025 | $615.57M | 11.98% |
| 2024 | $549.69M | 15.62% |
| 2023 | $475.42M | -5.82% |
| 2022 | $504.79M | 4.91% |
| 2021 | $481.19M | 14.79% |
| 2020 | $419.21M | -34.70% |
| 2019 | $642.00M | -5.07% |
| 2018 | $676.28M | 5.93% |
| 2017 | $638.43M | 15.63% |
| 2016 | $552.15M | 3.10% |
| 2015 | $535.54M | 15.07% |
| 2014 | $465.40M | 21.29% |
| 2013 | $383.71M | 30.83% |
| 2012 | $293.29M | 25.36% |
| 2011 | $233.95M | 18.99% |
| 2010 | $196.62M | 58.00% |
| 2009 | $124.44M | 61.08% |
| 2008 | $77.26M | 61.43% |
| 2007 | $47.86M | 83.90% |
| 2006 | $26.02M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $11.58B | 1,544.78% |
US
|
|
| $34.74B | 4,834.71% |
FR
|
|
| - | - |
JP
|
|
| $20.84B | 2,860.41% |
US
|
|
| - | - |
CH
|
